IndustryCompany release

ANI Pharmaceuticals launches SEK 5.6bn recommended offer for Egetis, maker of Emcitate

🇺🇸 Ani Pharmaceuticals Inc (ANIP) · Thu 05 Nov 2026

ANI Pharmaceuticals has proposed buying Egetis Therapeutics at SEK 11.25 a share, gaining Emcitate, approved in the EU and US for peripheral thyrotoxicosis in MCT8 deficiency.

ANI Pharmaceuticals announced on 5 November 2026 a recommended public offer to acquire Egetis Therapeutics. The price is SEK 11.25 per share, valuing the Swedish company at roughly SEK 5.6 billion.

Egetis' lead product is Emcitate (tiratricol), authorised for peripheral thyrotoxicosis in patients with MCT8 deficiency. It received EU approval in February 2025, and the US Food and Drug Administration followed on 28 September 2026.

The transaction is conditional on acceptance by holders of at least 90% of Egetis shares, as well as on regulatory approvals. The acceptance period is expected to run from about 20 November to 18 December 2026.

The information available does not give further detail on the approvals required, the financing of the deal or the timetable for completion.

What it means for your team

  • Teams tracking rare-disease portfolios should note that Emcitate, now approved on both sides of the Atlantic, is set to change ownership if the offer completes.
  • Marketing authorisation holder details, and the pharmacovigilance and quality responsibilities attached to them, could be affected after any completed acquisition. Watch for notices of any transfer.
  • Market-access teams should monitor the acceptance period, expected from about 20 November to 18 December 2026, and the 90% threshold.

Company's press release (SEC filing): Ani Pharmaceuticals Inc ↗

Article written by VigiEye from the official source (Ani Pharmaceuticals Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →